Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Schön T[au]:

Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Schön T et al. Clin Microbiol Infect. (2017)

[Not Available]. Schön T et al. Ther Umsch. (2016)

Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints. Schön T et al. Int J Infect Dis. (2017)

Search results

Items: 1 to 50 of 109

1.

Stable, Dual Redox Unit Organic Electrodes.

An SY, Schon TB, Seferos DS.

ACS Omega. 2020 Jan 7;5(2):1134-1141. doi: 10.1021/acsomega.9b03355. eCollection 2020 Jan 21.

2.

Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis.

Schulman H, Niward K, Abate E, Idh J, Axenram P, Bornefall A, Forsgren S, Jakobsson J, Öhrling C, Kron M, Brudin L, Diro E, Getachew Kebede A, Paues J, Bruchfeld J, Wejse C, Stendahl O, Schön T.

Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1155-1161. doi: 10.5588/ijtld.18.0634.

PMID:
31718751
3.

The evaluation of routine immunological tests to estimate the risk of progression into active tuberculosis.

Schön T.

Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1127-1128. doi: 10.5588/ijtld.19.0477. No abstract available.

PMID:
31718746
4.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
5.

Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.

Svensson RJ, Niward K, Davies Forsman L, Bruchfeld J, Paues J, Eliasson E, Schön T, Simonsson USH.

Br J Clin Pharmacol. 2019 Oct;85(10):2341-2350. doi: 10.1111/bcp.14048. Epub 2019 Jul 25.

PMID:
31269277
6.

The global prevalence of latent tuberculosis: a systematic review and meta-analysis.

Cohen A, Mathiasen VD, Schön T, Wejse C.

Eur Respir J. 2019 Sep 12;54(3). pii: 1900655. doi: 10.1183/13993003.00655-2019. Print 2019 Sep.

PMID:
31221810
7.

Polymorphisms in CARD8 and NLRP3 are associated with extrapulmonary TB and poor clinical outcome in active TB in Ethiopia.

Abate E, Blomgran R, Verma D, Lerm M, Fredrikson M, Belayneh M, Söderkvist P, Stendahl O, Schön T.

Sci Rep. 2019 Feb 28;9(1):3126. doi: 10.1038/s41598-019-40121-8.

8.

Standards for MIC testing that apply to the majority of bacterial pathogens should also be enforced for Mycobacterium tuberculosis complex.

Schön T, Matuschek E, Mohamed S, Utukuri M, Heysell S, Alffenaar JW, Shin S, Martinez E, Sintchenko V, Maurer FP, Keller PM, Kahlmeter G, Köser CU.

Clin Microbiol Infect. 2019 Apr;25(4):403-405. doi: 10.1016/j.cmi.2019.01.019. Epub 2019 Feb 14. No abstract available.

PMID:
30771527
9.

Unusual Capacity Increases with Cycling for Ladder-Type Microporous Polymers.

Schon TB, An SY, Tilley AJ, Seferos DS.

ACS Appl Mater Interfaces. 2019 Jan 16;11(2):1739-1747. doi: 10.1021/acsami.8b18293. Epub 2019 Jan 7.

PMID:
30614678
10.

HIV Interferes with the Dendritic Cell-T Cell Axis of Macrophage Activation by Shifting Mycobacterium tuberculosis-Specific CD4 T Cells into a Dysfunctional Phenotype.

Singh SK, Larsson M, Schön T, Stendahl O, Blomgran R.

J Immunol. 2019 Feb 1;202(3):816-826. doi: 10.4049/jimmunol.1800523. Epub 2018 Dec 28.

11.

Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.

Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J.

Clin Infect Dis. 2019 Sep 27;69(8):1394-1402. doi: 10.1093/cid/ciy1068.

PMID:
30561569
12.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

13.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J.

BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899.

14.

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.

Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T.

J Antimicrob Chemother. 2018 Oct 1;73(10):2838-2845. doi: 10.1093/jac/dky268.

PMID:
30124844
15.

Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".

Köser CU, Heyckendorf J, Andres S, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00616-18. doi: 10.1128/AAC.00616-18. Print 2018 Aug. No abstract available.

16.

Intermuscular Coherence Between Surface EMG Signals Is Higher for Monopolar Compared to Bipolar Electrode Configurations.

Mohr M, Schön T, von Tscharner V, Nigg BM.

Front Physiol. 2018 May 17;9:566. doi: 10.3389/fphys.2018.00566. eCollection 2018.

17.

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis.

Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T.

J Intern Med. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print]

PMID:
29806961
18.

Adipose tissue-derived stem cells from affected and unaffected areas in patients with multiple symmetric lipomatosis show differential regulation of mTOR pathway genes.

Felthaus O, Schön T, Schiltz D, Aung T, Kühlmann B, Jung F, Anker A, Klein S, Prantl L.

Clin Hemorheol Microcirc. 2018;69(1-2):141-151. doi: 10.3233/CH-189107.

PMID:
29758934
19.

Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.

Niward K, Ek Blom L, Davies Forsman L, Bruchfeld J, Eliasson E, Schön T, Chryssanthou E, Paues J.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00218-18. doi: 10.1128/AAC.00218-18. Print 2018 May.

20.

Gene expression of the two developmentally regulated dermatan sulfate epimerases in the Xenopus embryo.

Gouignard N, Schön T, Holmgren C, Strate I, Taşöz E, Wetzel F, Maccarana M, Pera EM.

PLoS One. 2018 Jan 25;13(1):e0191751. doi: 10.1371/journal.pone.0191751. eCollection 2018.

21.

Porous Carbon with Willow-Leaf-Shaped Pores for High-Performance Supercapacitors.

Shi Y, Zhang L, Schon TB, Li H, Fan C, Li X, Wang H, Wu X, Xie H, Sun H, Seferos DS, Zhang J.

ACS Appl Mater Interfaces. 2017 Dec 13;9(49):42699-42707. doi: 10.1021/acsami.7b12776. Epub 2017 Nov 28.

PMID:
29148706
22.

What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01550-17. doi: 10.1128/AAC.01550-17. Print 2018 Feb.

23.

A borderline range for Quantiferon Gold In-Tube results.

Jonsson J, Westman A, Bruchfeld J, Sturegård E, Gaines H, Schön T.

PLoS One. 2017 Nov 2;12(11):e0187313. doi: 10.1371/journal.pone.0187313. eCollection 2017.

24.

Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation.

Chesov D, Ciobanu N, Lange C, Schön T, Heyckendorf J, Crudu V.

Eur Respir J. 2017 Oct 12;50(4). pii: 1701752. doi: 10.1183/13993003.01752-2017. Print 2017 Oct. No abstract available.

25.

Role of Alanine Racemase Mutations in Mycobacterium tuberculosis d-Cycloserine Resistance.

Nakatani Y, Opel-Reading HK, Merker M, Machado D, Andres S, Kumar SS, Moradigaravand D, Coll F, Perdigão J, Portugal I, Schön T, Nair D, Devi KRU, Kohl TA, Beckert P, Clark TG, Maphalala G, Khumalo D, Diel R, Klaos K, Aung HL, Cook GM, Parkhill J, Peacock SJ, Swaminathan S, Viveiros M, Niemann S, Krause KL, Köser CU.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01575-17. doi: 10.1128/AAC.01575-17. Print 2017 Dec.

26.

Epidemiological characterization of a nosocomial outbreak of extended spectrum β-lactamase Escherichia coli ST-131 confirms the clinical value of core genome multilocus sequence typing.

Woksepp H, Ryberg A, Berglind L, Schön T, Söderman J.

APMIS. 2017 Dec;125(12):1117-1124. doi: 10.1111/apm.12753. Epub 2017 Sep 28.

PMID:
28960453
27.

Reduced susceptibility of clinical strains of Mycobacterium tuberculosis to reactive nitrogen species promotes survival in activated macrophages.

Idh J, Andersson B, Lerm M, Raffetseder J, Eklund D, Woksepp H, Werngren J, Mansjö M, Sundqvist T, Stendahl O, Schön T.

PLoS One. 2017 Jul 13;12(7):e0181221. doi: 10.1371/journal.pone.0181221. eCollection 2017.

28.

Chemically Addressable Perovskite Nanocrystals for Light-Emitting Applications.

Sun H, Yang Z, Wei M, Sun W, Li X, Ye S, Zhao Y, Tan H, Kynaston EL, Schon TB, Yan H, Lu ZH, Ozin GA, Sargent EH, Seferos DS.

Adv Mater. 2017 Sep;29(34). doi: 10.1002/adma.201701153. Epub 2017 Jul 10.

PMID:
28692786
29.

Vitamin D deficiency among newly diagnosed tuberculosis patients and their household contacts: a comparative cross-sectional study.

Workineh M, Mathewos B, Moges B, Gize A, Getie S, Stendahl O, Schon T, Abate E.

Arch Public Health. 2017 Jun 19;75:25. doi: 10.1186/s13690-017-0195-7. eCollection 2017.

30.

Three-Dimensional Arylene Diimide Frameworks for Highly Stable Lithium Ion Batteries.

Schon TB, Tilley AJ, Kynaston EL, Seferos DS.

ACS Appl Mater Interfaces. 2017 May 10;9(18):15631-15637. doi: 10.1021/acsami.7b02336. Epub 2017 May 2.

PMID:
28430407
31.

Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDRsl Assays.

Ajileye A, Alvarez N, Merker M, Walker TM, Akter S, Brown K, Moradigaravand D, Schön T, Andres S, Schleusener V, Omar SV, Coll F, Huang H, Diel R, Ismail N, Parkhill J, de Jong BC, Peto TE, Crook DW, Niemann S, Robledo J, Smith EG, Peacock SJ, Köser CU.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02169-16. doi: 10.1128/AAC.02169-16. Print 2017 Apr.

32.

Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints.

Schön T, Chryssanthou E.

Int J Infect Dis. 2017 Feb;55:122-124. doi: 10.1016/j.ijid.2016.12.027. Epub 2017 Jan 6.

33.

High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.

Woksepp H, Hällgren A, Borgström S, Kullberg F, Wimmerstedt A, Oscarsson A, Nordlund P, Lindholm ML, Bonnedahl J, Brudin L, Carlsson B, Schön T.

Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):553-563. doi: 10.1007/s10096-016-2832-4. Epub 2016 Nov 4.

PMID:
27815778
34.

Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.

Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E.

Clin Microbiol Infect. 2017 Mar;23(3):154-160. doi: 10.1016/j.cmi.2016.10.022. Epub 2016 Nov 1. Review.

35.

Vorhofflimmern.

Schön T, Kühne M.

Ther Umsch. 2016;73(6):333-9. doi: 10.1024/0040-5930/a000801. Review. German. No abstract available.

PMID:
27646431
36.

A microbiological method for determining serum levels of broad spectrum β-lactam antibiotics in critically ill patients.

Fridlund J, Woksepp H, Schön T.

J Microbiol Methods. 2016 Oct;129:23-27. doi: 10.1016/j.mimet.2016.07.020. Epub 2016 Jul 25.

PMID:
27469351
37.

Correction: The rise of organic electrode materials for energy storage.

Schon TB, McAllister BT, Li PF, Seferos DS.

Chem Soc Rev. 2016 Nov 7;45(22):6405-6406.

PMID:
27420289
38.

Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.

Yu X, Wang G, Chen S, Wei G, Shang Y, Dong L, Schön T, Moradigaravand D, Parkhill J, Peacock SJ, Köser CU, Huang H.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5232-7. doi: 10.1128/AAC.00393-16. Print 2016 Sep.

39.

The rise of organic electrode materials for energy storage.

Schon TB, McAllister BT, Li PF, Seferos DS.

Chem Soc Rev. 2016 Nov 7;45(22):6345-6404. Review. Erratum in: Chem Soc Rev. 2016 Nov 7;45(22):6405-6406.

PMID:
27273252
40.

Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Int J Mycobacteriol. 2015 Mar;4 Suppl 1:80-1. doi: 10.1016/j.ijmyco.2014.10.018. Epub 2014 Nov 11.

41.

Plasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count.

Skogmar S, Schön T, Balcha TT, Sturegård E, Jansson M, Björkman P.

PLoS One. 2015 Dec 2;10(12):e0144292. doi: 10.1371/journal.pone.0144292. eCollection 2015.

42.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T.

J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3.

PMID:
26538509
43.

Asymptomatic Helminth Infection in Active Tuberculosis Is Associated with Increased Regulatory and Th-2 Responses and a Lower Sputum Smear Positivity.

Abate E, Belayneh M, Idh J, Diro E, Elias D, Britton S, Aseffa A, Stendahl O, Schön T.

PLoS Negl Trop Dis. 2015 Aug 6;9(8):e0003994. doi: 10.1371/journal.pntd.0003994. eCollection 2015 Aug.

44.

Thiophene, Selenophene, and Tellurophene-based Three-Dimensional Organic Frameworks.

Li PF, Schon TB, Seferos DS.

Angew Chem Int Ed Engl. 2015 Aug 3;54(32):9361-6. doi: 10.1002/anie.201503418. Epub 2015 Jun 19.

PMID:
26096538
45.

Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.

46.

A Clinical Scoring Algorithm for Determination of the Risk of Tuberculosis in HIV-Infected Adults: A Cohort Study Performed at Ethiopian Health Centers.

Balcha TT, Skogmar S, Sturegård E, Schön T, Winqvist N, Reepalu A, Jemal ZH, Tibesso G, Björk J, Björkman P.

Open Forum Infect Dis. 2014 Oct 10;1(3):ofu095. doi: 10.1093/ofid/ofu095. eCollection 2014 Dec.

47.

Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.

Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G, Giske CG, Kahlmeter G, Schön T.

Clin Microbiol Infect. 2015 Feb;21(2):148.e5-7. doi: 10.1016/j.cmi.2014.08.021. Epub 2014 Oct 29.

48.

Worms and Humans: A Happy Divorce?

Akuffo H, Britton S, Schön T.

For Immunopathol Dis Therap. 2015;6(1-2):27-32. doi: 10.1615/ForumImmunDisTher.2015015300.

49.

Effects of albendazole on the clinical outcome and immunological responses in helminth co-infected tuberculosis patients: a double blind randomised clinical trial.

Abate E, Elias D, Getachew A, Alemu S, Diro E, Britton S, Aseffa A, Stendahl O, Schön T.

Int J Parasitol. 2015 Feb;45(2-3):133-40. doi: 10.1016/j.ijpara.2014.09.006. Epub 2014 Dec 5.

PMID:
25486494
50.

Antimycobacterial activity of selected medicinal plants traditionally used in Sudan to treat infectious diseases.

Abuzeid N, Kalsum S, Koshy RJ, Larsson M, Glader M, Andersson H, Raffetseder J, Pienaar E, Eklund D, Alhassan MS, AlGadir HA, Koko WS, Schön T, Ahmed Mesaik M, Abdalla OM, Khalid A, Lerm M.

J Ethnopharmacol. 2014 Nov 18;157:134-9. doi: 10.1016/j.jep.2014.09.020. Epub 2014 Sep 28.

PMID:
25261689

Supplemental Content

Support Center